{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:47:49Z","timestamp":1782143269237,"version":"3.54.5"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"unspecified","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lipum AB"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,5,17]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Bile salt-stimulated lipase (BSSL) is a digestive lipolytic enzyme and a potential novel drug target for treatment of rheumatoid arthritis (RA). Here, we report the results of the first-in-human study of SOL-116, a first-in-class humanised IgG4 monoclonal antibody targeting BSSL, conducted in healthy participants and patients with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a randomised, double-blind, placebo-controlled study of ascending single doses (0.075\u20136.075\u2009mg\/kg) and multiple doses (4 doses of 3.0\u2009mg\/kg every 4 weeks) of subcutaneously administered SOL-116 in healthy participants, as well as a single dose (2.025\u2009mg\/kg) in patients with RA. Safety and tolerability were assessed as the primary objective and pharmacokinetics (PK) and immunogenicity as secondary objectives. Exploratory objectives included evaluating BSSL concentrations and inflammatory markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SOL-116 was safe and well tolerated at the tested dose levels in 48 healthy participants and 8 patients with RA. There was a dose-proportional increase in area under the curve and maximum concentration across the single dose cohorts in healthy participants, with comparable PK characteristics between healthy participants and patients with RA and a low frequency of anti-drug antibodies. Notably, SOL-116 effectively reduced free BSSL levels in circulation, confirming target engagement although no clear changes in other exploratory inflammation markers were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated that SOL-116 has a favourable safety and PK profile. Combined with effective reduction of free BSSL in the circulation, findings in this study support ongoing clinical development of SOL-116, with a focus on elucidating the efficacy and mechanism of action of BSSL in the treatment of chronic inflammation, primarily RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05576012\">NCT05576012<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006712","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:56:19Z","timestamp":1782140179000},"page":"e006712","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct05576012","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-6531","authenticated-orcid":false,"given":"Anouk C","family":"Meijs","sequence":"first","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"},{"name":"Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Kolmert","sequence":"additional","affiliation":[{"name":"Lipum AB, Ume\u00e5, Sweden"},{"name":"Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Lindquist","sequence":"additional","affiliation":[{"name":"Lipum AB, Ume\u00e5, Sweden"},{"name":"Department of Clinical Sciences, Pediatrics, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hovstadius","sequence":"additional","affiliation":[{"name":"Lipum AB, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika W","family":"Grievink","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneli","family":"H\u00e4llgren","sequence":"additional","affiliation":[{"name":"Lipum AB, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Wennerholm","sequence":"additional","affiliation":[{"name":"Lipum AB, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi B","family":"Klarenbeek","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Hernell","sequence":"additional","affiliation":[{"name":"Lipum AB, Ume\u00e5, Sweden"},{"name":"Department of Clinical Sciences, Pediatrics, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026062207552004000_12.2.e006712.1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000615","article-title":"Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment","volume":"4","author":"Taylor","year":"2018","journal-title":"RMD Open"},{"key":"2026062207552004000_12.2.e006712.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070856","article-title":"Therapeutic advances in rheumatoid arthritis","volume":"384","author":"Brown","year":"2024","journal-title":"BMJ"},{"key":"2026062207552004000_12.2.e006712.3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/acr2.11266","article-title":"What is the persistence to methotrexate in rheumatoid arthritis, and does machine learning outperform hypothesis-based approaches to its prediction?","volume":"3","author":"Westerlind","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2026062207552004000_12.2.e006712.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2026062207552004000_12.2.e006712.5","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00211-4"},{"key":"2026062207552004000_12.2.e006712.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047006","article-title":"Bile salt-stimulated lipase plays an unexpected role in arthritis development in rodents","volume":"7","author":"Lindquist","year":"2012","journal-title":"PLoS One"},{"key":"2026062207552004000_12.2.e006712.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289980","article-title":"Effects of bile salt-stimulated lipase on blood cells and associations with disease activity in human inflammatory joint disorders","volume":"18","author":"Lindquist","year":"2023","journal-title":"PLoS One"},{"key":"2026062207552004000_12.2.e006712.8","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(81)80636-9"},{"key":"2026062207552004000_12.2.e006712.9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0005-2760(74)90254-9","article-title":"Human milk lipases. II. Bile salt-stimulated lipase","volume":"369","author":"Hernell","year":"1974","journal-title":"Biochim Biophys Acta"},{"key":"2026062207552004000_12.2.e006712.10","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e328337bbf0"},{"key":"2026062207552004000_12.2.e006712.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-026-01191-x","article-title":"Serum bile salt-stimulated lipase levels associates with systemic inflammation and declines with effect of treatment in juvenile idiopathic arthritis","volume":"24","author":"Berntson","year":"2026","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026062207552004000_12.2.e006712.12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/annrheumdis-2022-eular.3680","article-title":"POS0434 A novel target for treatment of inflammatory joint diseases","volume":"81","author":"Lindquist","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026062207552004000_12.2.e006712.13","unstructured":"Olink Proteomics AB . Validation data target 48 cytokine. 2023. Available: https:\/\/olink.com\/products\/olink-target-48 [Accessed 4 Jul 2025]."},{"key":"2026062207552004000_12.2.e006712.14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1203\/00006450-200210000-00009","article-title":"Does bile salt-stimulated lipase affect cholesterol uptake when bound to rat intestinal mucosa in vitro?","volume":"52","author":"F\u00e4lt","year":"2002","journal-title":"Pediatr Res"},{"key":"2026062207552004000_12.2.e006712.15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.12.7196"},{"key":"2026062207552004000_12.2.e006712.16","doi-asserted-by":"publisher","DOI":"10.1021\/bi981679a"},{"key":"2026062207552004000_12.2.e006712.17","doi-asserted-by":"publisher","DOI":"10.1159\/000266284"},{"key":"2026062207552004000_12.2.e006712.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"2026062207552004000_12.2.e006712.19","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2744(80)90050-9"},{"key":"2026062207552004000_12.2.e006712.20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/j.1552-4604.1996.tb04230.x","article-title":"The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers","volume":"36","author":"Melia","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"2026062207552004000_12.2.e006712.21","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(88)90260-3"},{"key":"2026062207552004000_12.2.e006712.22","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-001-0788-3"},{"key":"2026062207552004000_12.2.e006712.23","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"2026062207552004000_12.2.e006712.24","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-199309000-00009"},{"key":"2026062207552004000_12.2.e006712.25","first-page":"441","article-title":"On the source of bile salt-stimulated lipase in human milk","volume":"4","author":"Bl\u00e4ckberg","year":"1985","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026062207552004000_12.2.e006712.26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32655"},{"key":"2026062207552004000_12.2.e006712.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.42.5.545"},{"key":"2026062207552004000_12.2.e006712.28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00593-06"},{"key":"2026062207552004000_12.2.e006712.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000408"},{"key":"2026062207552004000_12.2.e006712.30","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E02-08-0544"},{"key":"2026062207552004000_12.2.e006712.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.01.034"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:56:25Z","timestamp":1782140185000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2026-006712"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006712","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}